Delving into the Latest Updates on Shandong Xingrui Biotechnology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Nervous System Diseases

Skin and Musculoskeletal Diseases

Stem cell therapy

CAR-M

in vivo CAR-T therapy

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Nervous System Diseases	1
Immune System Diseases	1

Top 5 Drug Type	Count

Stem cell therapy	1
CAR-M	1
in vivo CAR-T therapy	1

Top 5 Target	Count

CD133	1
GPC3(Glypican-3)	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Jun 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

1

Phase 2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Xinbang Stem Cells (Shandong Xingrui)	Osteoarthritis, Knee More	Phase 2
CD133 Targeted CAR-Macrophage(Qilu Pharmaceutical/Shandong Xingrui Biotechnology/Yinfeng Biological Engineering Group/Shandong University) ( CD133 )	Glioblastoma More	Preclinical
GPC3 CAR-T(Xingrui) ( GPC3 )	Solid tumor More	Preclinical